Ward A - Search Results

1

Economic assessments of low molecular weight heparin in venous thromboembolism.

Ward A, Getsios D, O'Brien J, Caro JJ. Ward A, et al. Expert Rev Pharmacoecon Outcomes Res. 2004 Feb;4(1):39-47. doi: 10.1586/14737167.4.1.39. Expert Rev Pharmacoecon Outcomes Res. 2004. PMID: 19807334

2

Managing diabetic foot ulcers: economic consequences in the USA.

O Brien J, Ward A, Salas M. O Brien J, et al. Among authors: ward a. Expert Rev Pharmacoecon Outcomes Res. 2003 Feb;3(1):25-32. doi: 10.1586/14737167.3.1.25. Expert Rev Pharmacoecon Outcomes Res. 2003. PMID: 19807492

3

Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.

Caro JJ, Salas M, Ward A, Getsios D, Mehnert A; AHEAD Study Group. Assessment of Health Economics in Alzheimer's Disease. Caro JJ, et al. Among authors: ward a. Dement Geriatr Cogn Disord. 2002;14(2):84-9. doi: 10.1159/000064929. Dement Geriatr Cogn Disord. 2002. PMID: 12145455

4

Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.

Salas M, Ward A, Caro J. Salas M, et al. Among authors: ward a. Clin Ther. 2002 Oct;24(10):1690-705. doi: 10.1016/s0149-2918(02)80072-8. Clin Ther. 2002. PMID: 12462297

5

Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F. Caro J, et al. Among authors: ward a. Drugs Aging. 2004;21(10):677-86. doi: 10.2165/00002512-200421100-00005. Drugs Aging. 2004. PMID: 15287825

6

Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France.

Ward A, Caro J, Bassinet L, Housset B, O'Brien JA, Guiso N. Ward A, et al. Infect Control Hosp Epidemiol. 2005 Mar;26(3):288-92. doi: 10.1086/502541. Infect Control Hosp Epidemiol. 2005. PMID: 15796282

7

Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus.

Ward A, O'Brien JA, Salas M. Ward A, et al. Expert Opin Pharmacother. 2005 Apr;6(4):601-8. doi: 10.1517/14656566.6.4.601. Expert Opin Pharmacother. 2005. PMID: 15934886 Review.

8

Modelling the health benefits and economic implications of implanting dual-chamber vs. single-chamber ventricular pacemakers in the UK.

Caro J, Ward A, Moller J. Caro J, et al. Among authors: ward a. Europace. 2006 Jun;8(6):449-55. doi: 10.1093/europace/eul042. Epub 2006 May 11. Europace. 2006. PMID: 16690630

9

Modelling the economic and health consequences of cardiac resynchronization therapy in the UK.

Caro JJ, Guo S, Ward A, Chalil S, Malik F, Leyva F. Caro JJ, et al. Among authors: ward a. Curr Med Res Opin. 2006 Jun;22(6):1171-9. doi: 10.1185/030079906X112516. Curr Med Res Opin. 2006. PMID: 16846550

10

Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone.

Caro JJ, Ward A, Deniz HB, O'Brien JA, Ehreth JL. Caro JJ, et al. Among authors: ward a. Value Health. 2007 Jan-Feb;10(1):13-22. doi: 10.1111/j.1524-4733.2006.00140.x. Value Health. 2007. PMID: 17261112 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,379 results

Search Page

Filters